ZVRA vs. EXE
ZVRA (Zevra Therapeutics Inc.) and EXE (Expand Energy Corp) are both stocks. ZVRA operates in Biotechnology (Healthcare), while EXE operates in Oil & Gas E&P (Energy). Over the past 5 years, ZVRA returned -2.85%/yr vs 14.81%/yr for EXE. At a 0.14 correlation, their price movements are largely independent.
Performance
ZVRA vs. EXE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ZVRA achieves a 41.18% return, which is significantly higher than EXE's -18.63% return.
ZVRA
- 1D
- -2.47%
- 1M
- 13.76%
- YTD
- 41.18%
- 6M
- 51.86%
- 1Y
- 35.01%
- 3Y*
- 29.54%
- 5Y*
- -2.85%
- 10Y*
- -16.40%
EXE
- 1D
- 1.95%
- 1M
- -6.62%
- YTD
- -18.63%
- 6M
- -20.38%
- 1Y
- -20.29%
- 3Y*
- 6.27%
- 5Y*
- 14.81%
- 10Y*
- —
ZVRA vs. EXE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
ZVRA Zevra Therapeutics Inc. | 41.18% | 7.43% | 27.33% | 42.70% | -47.30% | -4.29% |
EXE Expand Energy Corp | -18.63% | 14.35% | 33.18% | -14.77% | 62.34% | 53.16% |
Correlation
The correlation between ZVRA and EXE is 0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.00 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.09 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.13 |
Correlation (All Time) Calculated using the full available price history since Feb 10, 2021 | 0.14 |
The correlation between ZVRA and EXE shifts across timeframes, from 0.00 (1 year) to 0.14 (all time), reflecting how their relationship changes across market environments.
Fundamentals
ZVRA:
$761.92M
EXE:
$21.37M
ZVRA:
$2.16
EXE:
$17.89
ZVRA:
5.85
EXE:
4.96
ZVRA:
5.94
EXE:
1.14
ZVRA:
3.70
EXE:
0.00
ZVRA:
$122.29M
EXE:
$14.10B
ZVRA:
$104.94M
EXE:
$8.89B
ZVRA:
$149.15M
EXE:
$7.00B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ZVRA vs. EXE — Risk / Return Rank
ZVRA
EXE
ZVRA vs. EXE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Zevra Therapeutics Inc. (ZVRA) and Expand Energy Corp (EXE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ZVRA | EXE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.20 | ||
| Sortino ratioReturn per unit of downside risk | +2.04 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 0.91 | +0.25 |
| Calmar ratioReturn relative to maximum drawdown | 0.81 | -0.72 | +1.53 |
| Martin ratioReturn relative to average drawdown | 1.41 | -1.31 | +2.72 |
Loading charts...
Drawdowns
ZVRA vs. EXE - Drawdown Comparison
The maximum ZVRA drawdown since its inception was -99.27%, which is greater than EXE's maximum drawdown of -29.69%. Use the drawdown chart below to compare losses from any high point for ZVRA and EXE.
Loading charts...
Drawdown Indicators
| ZVRA | EXE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.27% | -29.69% | -69.58% |
Max Drawdown (1Y)Largest decline over 1 year | -43.47% | -28.32% | -15.15% |
Max Drawdown (3Y)Largest decline over 3 years | -43.47% | -28.32% | -15.15% |
Max Drawdown (5Y)Largest decline over 5 years | -74.01% | -29.69% | -44.32% |
Max Drawdown (10Y)Largest decline over 10 years | -97.85% | — | — |
Current DrawdownCurrent decline from peak | -96.65% | -26.92% | -69.73% |
Average DrawdownAverage peak-to-trough decline | -86.41% | -10.98% | -75.43% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.87% | 15.50% | +9.37% |
Volatility
ZVRA vs. EXE - Volatility Comparison
Zevra Therapeutics Inc. (ZVRA) has a higher volatility of 24.56% compared to Expand Energy Corp (EXE) at 7.74%. This indicates that ZVRA's price experiences larger fluctuations and is considered to be riskier than EXE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ZVRA | EXE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 24.56% | 7.74% | +16.82% |
Volatility (6M)Calculated over the trailing 6-month period | 40.23% | 22.57% | +17.66% |
Volatility (1Y)Calculated over the trailing 1-year period | 62.90% | 31.76% | +31.14% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 60.49% | 35.13% | +25.36% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 81.46% | 34.78% | +46.68% |
Dividends
ZVRA vs. EXE - Dividend Comparison
ZVRA has not paid dividends to shareholders, while EXE's dividend yield for the trailing twelve months is around 3.59%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
EXE Expand Energy Corp | 3.59% | 2.89% | 2.45% | 4.70% | 10.16% | 1.74% |
ZVRA Zevra Therapeutics Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
ZVRA vs. EXE - Financials Comparison
This section allows you to compare key financial metrics between Zevra Therapeutics Inc. and Expand Energy Corp. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ZVRA and EXE have a correlation of 0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ZVRA has higher volatility (24.56%) compared to EXE (7.74%). In terms of maximum drawdown, ZVRA dropped -99.27% vs EXE's -29.69%.
ZVRA currently has the higher Sharpe Ratio (0.56 vs -0.64), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ZVRA and EXE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer